NEW YORK (GenomeWeb News) – Almac today said that it is teaming up with researchers at Queen's University, Belfast to develop pharmacogenomics tests for a variety of cancers.
Almac will work with Rcihard Kennedy at the university's Centre for Cancer Research and Cell Biology in looking for stratification markers for prostate, ovarian, and breast cancer. Lab facilities and staff costs are being funded by Invest Northern Ireland and The McClay Foundation. According to Almac, Invest NI has offered the partners £1.5 million ($2.4 million) to support the collaboration.
"The research will involve using cutting-edge technology developed by Almac, which will allows us to analyze large numbers of patient tumors collected by Queen's," Kennedy said in a statement. "We will develop tests to help clinicians better understand prostate, ovarian, and breast cancer and prescribe the appropriate treatments tailored to the specific patient."